TGTX Q3'26 Earnings: revenue estimate is 245.47M USD

What happened

TG Therapeutics is scheduled to announce its Q3'26 results on November 09, with the release expected at 7:00 AM ET. Analysts estimate revenue of 245.47 million USD and earnings per share, or profit allocated to each share, of 0.37 USD.

Confirmed

Global impact / market context

The results will show whether reported sales match the 245.47 million USD estimate and whether earnings per share reach 0.37 USD. A shortfall could weaken expectations for the company’s revenue and profit, while a beat could strengthen them, depending on investors’ response.

Analyst inference

The supplied figures put estimated Q3’26 revenue at 245.47 million USD, above the listed revenue estimates for earlier quarters. If results differ from that forecast, reported sales could influence investor expectations for TG Therapeutics’ near-term revenue and positioning in the stock.

Analyst inference

What to watch

1. Check the November 09 announcement for reported Q3'26 revenue against the 245.47 million USD estimate; the difference will show whether sales beat or missed expectations. Confirmed
2. Compare reported earnings per share with the 0.37 USD estimate; this measure is profit allocated to each share and indicates whether earnings met forecasts. Confirmed
3. If revenue or earnings fall short, investors could lower expectations for future sales and profit, potentially affecting how they value TG Therapeutics shares. Analyst inference

Evidence

• Original source link unavailable